New study shows benefits of intravenous epilepsy drug lamotrigine

New research has demonstrated the benefits of a new intravenous version of lamotrigine, an established treatment for epilepsy.

The University of Minnesota-led study involved the creation of a stable-labeled intravenous formulation of lamotrigine for studying pharmacokinetics in epilepsy patients. This administration method is useful in treating patients where oral administration is not possible.

A 50 mg dose of this new therapy option was given to 20 people with epilepsy, replacing their regular morning oral dose of the unlabeled, commercially available formulation of the drug.

It was shown there were no significant changes in blood pressure, heart rate or adverse events – including rash – associated with the intravenous lamotrigine formulation.

The researchers concluded: “Our results show that lamotrigine base that is complexed with 2-hydroxypropyl-beta-cyclodextrin and stable-labeled can be given safely as a tracer replacement dose.”

The drug is currently used to treat partial epilepsy, bipolar disorder, generalised epilepsy, Lennox-Gastaut syndrome and absence seizures. It helps to control electrical activity in the brain, thus reducing the chances of seizures.

Posted by Bob Jones

News Updates

Sign up for Research updates

News categories